J. Yau, S. Rogers, R. Kawasaki, E. Lamoureux, J. Kowalski et al., Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012.

L. Aiello, D. /. Edic-research, and . Group, Diabetic Retinopathy and Other Ocular Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study, Diabetes Care, vol.37, issue.1, pp.17-23, 2014.
DOI : 10.2337/dc13-2251

B. Fullerton, K. Jeitler, M. Seitz, K. Horvath, A. Berghold et al., Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus

C. Barr, Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, N

E. Group, J. Lachin, N. White, D. Hainsworth, W. Sun et al., Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of followup in the DCCT/EDIC. Diabetes. 2015 Feb Blood pressure control for diabetic retinopathy Long-term follow-up after tight control of blood pressure in type 2 diabetes Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group, CD006127. 12, pp.968-83, 1960.

M. Gillies, F. Sutter, J. Simpson, J. Larsson, H. Ali et al., Intravitreal Triamcinolone for Refractory Diabetic Macular EdemaTwo-Year Results of a Double-Masked, Placebo-Controlled, Randomized Clinical Trial, Ophthalmology, vol.113, issue.9, pp.1533-1541, 2006.
DOI : 10.1016/j.ophtha.2006.02.065

M. Gillies, I. Mcallister, M. Zhu, W. Wong, D. Louis et al., Intravitreal Triamcinolone Prior to Laser Treatment of Diabetic Macular Edema, Ophthalmology, vol.118, issue.5, pp.866-72, 2011.
DOI : 10.1016/j.ophtha.2010.09.029

J. Jonas, R. Degenring, B. Kamppeter, I. Kreissig, I. Akkoyun et al., Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema, Diabetic Retinopathy Clinical Research Network (DRCR.net), pp.158-601447, 1960.

D. Boyer, D. Faber, S. Gupta, S. Patel, H. Tabandeh et al., Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina Phila Pa, pp.915-938, 2011.

D. Boyer, Y. Yoon, R. Belfort, F. Bandello, R. Maturi et al., Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema, Ophthalmology, vol.121, issue.10, pp.1904-1918, 2014.
DOI : 10.1016/j.ophtha.2014.04.024

M. Scaramuzzi, G. Querques, C. Spina, R. Lattanzio, and F. Bandello, Repeated intravitreal dexamethasone implant (ozurdex) for diabetic macular edema. Retina Phila Pa, pp.1216-1238, 2015.

P. Campochiaro, D. Brown, A. Pearson, S. Chen, D. Boyer et al., Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, Ophthalmology, vol.119117119, issue.10611, pp.2125-2157, 2010.

M. Elman, N. Bressler, H. Qin, R. Beck, F. Ferris et al., Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema, Ophthalmology, vol.118, issue.4, pp.609-623, 2011.
DOI : 10.1016/j.ophtha.2010.12.033

P. Mitchell, F. Bandello, U. Schmidt-erfurth, G. Lang, P. Massin et al., The RESTORE Study, Ophthalmology, vol.118, issue.4, pp.615-640, 2011.
DOI : 10.1016/j.ophtha.2011.01.031

Q. Nguyen, S. Shah, A. Khwaja, R. Channa, E. Hatef et al., Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes

Q. Nguyen, S. Shah, J. Heier, D. Do, J. Lim et al., Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2, Ophthalmology, vol.116117, issue.116, pp.2175-81, 2009.

J. Arevalo, J. Sanchez, J. Fromow-guerra, L. Wu, M. Berrocal et al., Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up, Graefe's Archive for Clinical and Experimental Ophthalmology, vol.110, issue.6, pp.735-778, 2009.
DOI : 10.1007/s00417-008-1034-x

R. Rajendram, S. Fraser-bell, A. Kaines, M. Michaelides, R. Hamilton et al., A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema, Archives of Ophthalmology, vol.130, issue.8, pp.972-981, 1960.
DOI : 10.1001/archophthalmol.2012.393

D. Kook, A. Wolf, T. Kreutzer, A. Neubauer, R. Strauss et al., Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina Phila Pa, pp.1053-60, 2008.

A. Ho, I. Scott, S. Kim, G. Brown, M. Brown et al., Anti???Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema, Ophthalmology, vol.119, issue.10, pp.2179-88, 2012.
DOI : 10.1016/j.ophtha.2012.07.058

T. Otani, S. Kishi, J. Haller, H. Qin, R. Apte et al., A controlled study of vitrectomy for diabetic macular edema Diabetic Retinopathy Clinical Research Network Writing Committee Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction, Am J Ophthalmol Ophthalmology. Frank RN. Diabetic retinopathy. N Engl J Med, vol.134117350, issue.261, pp.214-223, 2002.

R. Klein, K. Lee, M. Knudtson, R. Gangnon, and B. Klein, Changes in Visual Impairment Prevalence by Period of Diagnosis of DiabetesThe Wisconsin Epidemiologic Study of Diabetic Retinopathy, Ophthalmology, vol.116, issue.10, pp.1937-1979, 2009.
DOI : 10.1016/j.ophtha.2009.03.012

S. Resnikoff, D. Pascolini, D. Etya-'ale, I. Kocur, R. Pararajasegaram et al., Global data on visual impairment in the year 2002. Bull World Health Organ, 2004.

R. Klein, B. Klein, S. Moss, M. Davis, and D. Demets, The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema, Ophthalmology, 1984.

N. Younis, D. Broadbent, J. Vora, S. Harding, R. Klein et al., Liverpool Diabetic Eye Study Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema, Lancet. Ophthalmology, vol.361102, issue.93531, pp.195-200, 1995.

R. Klein, S. Moss, B. Klein, M. Davis, and D. Demets, The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema, Ophthalmology, 1989.

H. Zhou, D. Isaman, S. Messinger, M. Brown, R. Klein et al., A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care, pp.2856-63, 2005.

P. Hovind, L. Tarnow, K. Rossing, P. Rossing, S. Eising et al., Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care, 2003.

R. Varma, N. Bressler, Q. Doan, M. Gleeson, M. Danese et al., Prevalence of and Risk Factors for Diabetic Macular Edema in the United States, JAMA Ophthalmology, vol.132, issue.11, pp.1334-1374, 2014.
DOI : 10.1001/jamaophthalmol.2014.2854

R. Klein, K. Lee, R. Gangnon, and B. Klein, The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus, Ophthalmology, vol.117, issue.1, pp.63-70, 2010.
DOI : 10.1016/j.ophtha.2009.06.051

R. Klein, M. Knudtson, K. Lee, R. Gangnon, and B. Klein, The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: The Twenty-five-Year Incidence of Macular Edema in Persons with Type 1 Diabetes, Ophthalmology, vol.116, issue.3, pp.497-503, 2009.
DOI : 10.1016/j.ophtha.2008.10.016

R. Tapp, J. Shaw, C. Harper, M. De-courten, B. Balkau et al., The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care, pp.1731-1738, 2003.

A. Sjølie, J. Stephenson, S. Aldington, E. Kohner, J. H. Stevens et al., Retinopathy and Vision Loss in Insulin-dependent Diabetes in Europe, Ophthalmology, vol.104, issue.2, pp.252-60, 1997.
DOI : 10.1016/S0161-6420(97)30327-3

E. Kohner and . Microvascular-disease, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes, UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet Lond Engl, pp.20-24, 1993.

D. Nathan, P. Cleary, J. Backlund, S. Genuth, J. Lachin et al., Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N Engl J Med, vol.353, issue.25, pp.2643-53, 2005.

R. Klein, B. Klein, S. Moss, M. Davis, and D. Demets, Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med, 1989.

D. Matthews, I. Stratton, S. Aldington, R. Holman, E. Kohner et al., UK Prospective Diabetes Study Group Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69 The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate, The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study, pp.1631-401261, 1960.

H. Hammes, R. Welp, H. Kempe, C. Wagner, E. Siegel et al., Risk Factors for Retinopathy and DME in Type 2 Diabetes-Results from the German/Austrian DPV Database):e0132492. 63 Serum Lipids and Proliferative Diabetic Retinopathy and Macular Edema in Persons With Long-term Type 1 Diabetes Mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy, PloS One. JAMA Ophthalmol, vol.10, issue.7, 2015.

P. Massin, A. Erginay, C. Fraser, S. Clark, R. Mason et al., The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema. Ophthalmology High prevalence of sleep disordered breathing in patients with diabetic macular edema. Retina Phila Pa Visual improvement following continuous positive airway pressure therapy in diabetic subjects with clinically significant macular oedema and obstructive sleep apnoea: proof of principle study, Respir Int Rev Thorac Dis, vol.1153284, issue.394, pp.533-542, 2008.

L. Knudsen, H. Lervang, S. Lundbye-christensen, A. Gorst-rasmussen, D. Browning et al., The North Jutland County Diabetic Retinopathy Study (NCDRS) 2. Non-ophthalmic parameters and clinically significant macular oedema HAS. Haute Autorité de Santé-Rapport sur la tomographie du segment postérieur par scanographie à cohérence optique Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography, Br J Ophthalmol. Ophthalmology, vol.91111, issue.704, pp.1593-1598, 2004.

G. Virgili, F. Menchini, V. Murro, E. Peluso, F. Rosa et al., Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy Central retinal thickness measured with HD-OCT shows a weak correlation with visual acuity in eyes with CSME, CD008081. 72. Nunes S, 2011.

O. Comyn, L. Heng, F. Ikeji, K. Bibi, P. Hykin et al., Repeatability of Spectralis OCT Measurements of Macular Thickness and Volume in Diabetic Macular Edema, Investigative Opthalmology & Visual Science, vol.53, issue.12, pp.7754-7763, 2012.
DOI : 10.1167/iovs.12-10895

M. Menke, S. Dabov, P. Knecht, and V. Sturm, Reproducibility of Retinal Thickness Measurements in Healthy Subjects Using Spectralis Optical Coherence Tomography, American Journal of Ophthalmology, vol.147, issue.3, pp.467-72, 2009.
DOI : 10.1016/j.ajo.2008.09.005

J. Lammer, C. Scholda, C. Prünte, T. Benesch, U. Schmidt-erfurth et al., RETINAL THICKNESS AND VOLUME MEASUREMENTS IN DIABETIC MACULAR EDEMA, Retina, vol.31, issue.1, pp.48-55, 2011.
DOI : 10.1097/IAE.0b013e3181e095a4

F. Forooghian, C. Cukras, C. Meyerle, E. Chew, and W. Wong, Evaluation of Time Domain and Spectral Domain Optical Coherence Tomography in the Measurement of Diabetic Macular Edema, Investigative Opthalmology & Visual Science, vol.49, issue.10, pp.4290-4296, 2008.
DOI : 10.1167/iovs.08-2113

L. Pelosini, C. Hull, J. Boyce, D. Mchugh, M. Stanford et al., Optical Coherence Tomography May Be Used to Predict Visual Acuity in Patients with Macular Edema, Investigative Opthalmology & Visual Science, vol.52, issue.5, pp.2741-2749, 2011.
DOI : 10.1167/iovs.09-4493

S. Gibran, K. Khan, S. Jungkim, and P. Cleary, Optical Coherence Tomographic Pattern May Predict Visual Outcome after Intravitreal Triamcinolone for Diabetic Macular Edema, Ophthalmology, vol.114, issue.5, pp.890-894, 2007.
DOI : 10.1016/j.ophtha.2006.11.026

N. Ghazi, J. Ciralsky, S. Shah, P. Campochiaro, and J. Haller, Optical Coherence Tomography Findings in Persistent Diabetic Macular Edema: The Vitreomacular Interface, American Journal of Ophthalmology, vol.144, issue.5
DOI : 10.1016/j.ajo.2007.07.012

T. Murakami, K. Nishijima, A. Sakamoto, M. Ota, T. Horii et al., Association of Pathomorphology, Photoreceptor Status, and Retinal Thickness With Visual Acuity in Diabetic Retinopathy, American Journal of Ophthalmology, vol.151, issue.2, pp.310-317, 2011.
DOI : 10.1016/j.ajo.2010.08.022

B. Gerendas, S. Waldstein, C. Simader, G. Deak, B. Hajnajeeb et al., Association of Disorganization of Retinal Inner Layers With Vision After Resolution of Center-Involved Diabetic Macular Edema, Threedimensional automated choroidal volume assessment on standard spectral-domain optical coherence tomography and correlation with the level of diabetic macular edema, pp.820-825, 2015.

I. Laíns, J. Figueira, A. Santos, A. Baltar, M. Costa et al., CHOROIDAL THICKNESS IN DIABETIC RETINOPATHY, Retina, vol.34, issue.6, 2014.
DOI : 10.1097/IAE.0000000000000053

N. Rayess, E. Rahimy, G. Ying, N. Bagheri, A. Ho et al., Baseline Choroidal Thickness as a Predictor for Response to Anti???Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema, American Journal of Ophthalmology, vol.159, issue.1, pp.85-91
DOI : 10.1016/j.ajo.2014.09.033

T. Otani and S. Kishi, Correlation between optical coherence tomography and fluorescein angiography findings in diabetic macular edema. Ophthalmology, 2007.

T. Horii, T. Murakami, K. Nishijima, T. Akagi, A. Uji et al., Relationship between fluorescein pooling and optical coherence tomographic reflectivity of cystoid spaces in diabetic macular edema Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group, Ophthalmology. Ophthalmology, vol.11998, issue.875, pp.1047-55, 1991.

P. Massin, K. Angioi-duprez, and F. Bacin, Recommandations de l'ALFEDIAM pour le dépistage et la surveillance de la rétinopathie diabétique Focal photocoagulation treatment of diabetic macular edema Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group Diabetic macular edema: what is focal and what is diffuse?, Diabetes Metab. Arch Ophthalmol Chic Ill Ophthalmology. Browning DJ, Altaweel MM, Bressler NM Am J Ophthalmol, vol.11398146, issue.655, pp.203-212, 1960.

G. Panozzo, B. Parolini, E. Gusson, A. Mercanti, S. Pinackatt et al., Diabetic macular edema: an OCT-based classification. Semin Ophthalmol Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial, Diabetes Control and Complications Trial Research Group. Ophthalmology, vol.19102, issue.124, pp.13-20, 1995.

R. Cohen, T. Lecaire, C. Lindsell, E. Smith, D. Alessio et al., Relationship of Prospective GHb to Glycated Serum Proteins in Incident Diabetic Retinopathy Implications of the glycation gap for mechanism of risk prediction. Diabetes Care, 2008.

E. Kohner, I. Stratton, S. Aldington, R. Holman, and D. Matthews, UK Prospective Diabetes Study (IKPDS) Group. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52), Diabet Med J Br Diabet Assoc, vol.18, issue.3, pp.178-84, 2001.

A. Scheen, N. Paquot, and P. Lefebvre, UKPDS): 10 years later] Rev Médicale Liège Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group, Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial, pp.624-633, 1960.

H. Gerstein, M. Miller, R. Byington, D. Goff, and J. Bigger, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, vol.358, issue.24, pp.2545-59, 2008.

. Accord-study-group, W. Cushman, G. Evans, R. Byington, D. Goff et al., Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med, vol.362, issue.17, pp.1575-85, 2010.

. Accord-study-group, H. Ginsberg, M. Elam, L. Lovato, J. Crouse et al., Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 2010.

. Accord-study, . Group, . Accord-eye-study, . Group, E. Chew et al., Effects of medical therapies on retinopathy progression in type 2 diabetes, N Engl J Med Jul, vol.15363, issue.3, pp.233-277, 2010.

P. Silva, J. Cavallerano, J. Sun, L. Aiello, and L. Aiello, Effect of systemic medications on onset and progression of diabetic retinopathy, Nature Reviews Endocrinology, vol.92, issue.9, 2010.
DOI : 10.1038/nrendo.2010.122

N. Wang, Z. Zheng, H. Jin, and X. Xu, Treatment effects of captopril on nonproliferative diabetic retinopathy, Chin Med J (Engl, vol.125, issue.2, pp.287-92

T. Wong, R. Simó, and P. Mitchell, Fenofibrate ??? A Potential Systemic Treatment for Diabetic Retinopathy?, American Journal of Ophthalmology, vol.154, issue.1, pp.6-12
DOI : 10.1016/j.ajo.2012.03.013

P. Massin, T. Peto, J. Ansquer, and P. Aubonnet, Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study, Ophthalmic Epidemiology, vol.366, issue.9500, pp.307-324, 2014.
DOI : 10.1016/j.ophtha.2010.02.031

. Photocoagulation-for-diabetic-macular-edema, Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group, Arch Ophthalmol Chic Ill, vol.103, issue.12, pp.1796-806, 1960.

S. Bressler, T. Almukhtar, L. Aiello, N. Bressler, F. Ferris et al., GREEN OR YELLOW LASER TREATMENT FOR DIABETIC MACULAR EDEMA, Retina, vol.33, issue.10, 2013.
DOI : 10.1097/IAE.0b013e318295f744

S. Vujosevic, E. Bottega, M. Casciano, E. Pilotto, E. Convento et al., MICROPERIMETRY AND FUNDUS AUTOFLUORESCENCE IN DIABETIC MACULAR EDEMA, Retina, vol.30, issue.6, pp.908-924, 2010.
DOI : 10.1097/IAE.0b013e3181c96986

S. Sivaprasad and G. Dorin, Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema, Expert Review of Medical Devices, vol.9, issue.2, pp.189-97
DOI : 10.1586/erd.12.1

A. Neubauer, J. Langer, R. Liegl, C. Haritoglou, A. Wolf et al., Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser, Clin Ophthalmol Auckl NZ, vol.7, pp.121-129, 2013.

I. Kozak, S. Oster, M. Cortes, D. Dowell, K. Hartmann et al., Clinical Evaluation and Treatment Accuracy in Diabetic Macular Edema Using Navigated Laser Photocoagulator NAVILAS, Ophthalmology, vol.118, issue.6, pp.1119-1143, 2011.
DOI : 10.1016/j.ophtha.2010.10.007

C. Haritoglou, D. Kook, A. Neubauer, A. Wolf, S. Priglinger et al., Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina Phila Pa, pp.999-1005, 2006.

M. Gillies, L. Lim, A. Campain, G. Quin, W. Salem et al., A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema, Ophthalmology, vol.121, issue.12, pp.2473-81, 2014.
DOI : 10.1016/j.ophtha.2014.07.002

L. Kodjikian, E. Souied, G. Mimoun, M. Mauget-faÿsse, F. Behar-cohen et al., Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial, Ophthalmology, vol.120, issue.11, pp.2300-2309, 2013.
DOI : 10.1016/j.ophtha.2013.06.020

Q. Nguyen, S. Tatlipinar, S. Shah, J. Haller, E. Quinlan et al., Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema, American Journal of Ophthalmology, vol.142, issue.6, pp.961-970, 2006.
DOI : 10.1016/j.ajo.2006.06.068

D. Retinopathy-clinical-research-network, M. Elman, H. Qin, L. Aiello, R. Beck et al., Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results, Ophthalmology, vol.119, issue.11, pp.2312-2320, 2012.

G. Lang, A. Berta, B. Eldem, C. Simader, D. Sharp et al., Two-Year Safety and Efficacy of Ranibizumab 0.5 mg in Diabetic Macular Edema, Ophthalmology, vol.120, issue.10, pp.2004-2016, 2013.
DOI : 10.1016/j.ophtha.2013.02.019

F. Fajnkuchen, C. Pru?-nte, and P. Massin, Efficacite et tole rance du traitement par ranibizumab administré selon un protocole treat-and-extend versus pro re nata pour une baisse d'acuité visuelle dûe à un oedème maculaire diabétique: étude RETAIN. Communication orale à la Société Française d'Ophtalmologie, Ophtalmologie, vol.2013

A. Nepomuceno, E. Takaki, F. Paes-de-almeida, R. Peroni, J. Cardillo et al., A Prospective Randomized Trial of Intravitreal Bevacizumab Versus Ranibizumab for the Management of??Diabetic Macular Edema, American Journal of Ophthalmology, vol.156, issue.3, pp.502-512, 2013.
DOI : 10.1016/j.ajo.2013.04.026

D. Do, Q. Nguyen, D. Boyer, U. Schmidt-erfurth, D. Brown et al., One-year outcomes of the da Vinci Study of VEGF Trap-Eye

D. Retinopathy-clinical-research, . Network, J. Wells, A. Glassman, A. Ayala et al., Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema, New England Journal of Medicine, vol.372, issue.13, pp.1193-203, 2015.
DOI : 10.1056/NEJMoa1414264

J. Mason, M. Somaiya, and R. Singh, Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina Phila Pa, 2004.

T. Yilmaz, C. Weaver, M. Gallagher, M. Cordero-coma, R. Cervantes-castaneda et al., Intravitreal Triamcinolone Acetonide Injection for Treatment of Refractory Diabetic Macular Edema, Ophthalmology, vol.116, issue.5, 2009.
DOI : 10.1016/j.ophtha.2009.02.002

H. Kwak, D. Amico, and D. , Evaluation of the Retinal Toxicity and Pharmacokinetics of Dexamethasone After Intravitreal Injection, Archives of Ophthalmology, vol.110, issue.2, 1960.
DOI : 10.1001/archopht.1992.01080140115038

M. Simunovic, A. Hunyor, and I. Ho, Vitrectomy for diabetic macular edema: a systematic review and meta-analysis, Canadian Journal of Ophthalmology / Journal Canadien d'Ophtalmologie, vol.49, issue.2, 2014.
DOI : 10.1016/j.jcjo.2013.11.012

N. Doi, T. Sakamoto, Y. Sonoda, M. Yasuda, K. Yonemoto et al., Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes, Graefe's Archive for Clinical and Experimental Ophthalmology, vol.246, issue.11, pp.71-79
DOI : 10.1007/s00417-011-1777-7

M. Smet and M. Castilla, Ocriplasmin for diabetic retinopathy, Expert Opinion on Biological Therapy, vol.35, issue.12, pp.1741-1748, 2013.
DOI : 10.1001/archopht.1993.01090020056023

D. Jusufbegovic, M. Mugavin, S. Schaal, . Evolution, . Controlling et al., Changing Trends in the Management of Diabetic Macular Edema at a Single Institution Over the Past Decade, Retina Phila Pa. 2015, vol.35, issue.5, pp.929-963

P. Campochiaro, D. Brown, A. Pearson, T. Ciulla, D. Boyer et al., Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema, Ophthalmology, vol.118, issue.4, pp.626-661, 2011.
DOI : 10.1016/j.ophtha.2010.12.028

F. Ghanchi, D. Retinopathy-guidelines-working, and . Group, The Royal College of Ophthalmologists??? clinical guidelines for diabetic retinopathy: a summary, Eye, vol.27, issue.2, pp.285-292, 2013.
DOI : 10.1038/eye.2012.287

A. Retina, /. Vitreous, and P. Panel, Hoskins Center for Quality Eye Care Diabetic Retinopathy PPP -2014 [Internet] Available from: http://www.aao.org/preferred-practice-pattern/diabetic-retinopathy, 2014.

. V. Gualino, Enquête des pratiques de la DMLA en France. Communication orale SFO. Société Française d'ophtalmologie, 2014.

F. Holz, R. Tadayoni, S. Beatty, A. Berger, M. Cereda et al., Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration, British Journal of Ophthalmology, vol.120, issue.2, pp.220-226, 2015.
DOI : 10.1136/bjophthalmol-2014-305327

S. Cohen, G. Mimoun, H. Oubraham, A. Zourdani, C. Malbrel et al., CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE, Retina, vol.33, issue.3, pp.474-81, 2013.
DOI : 10.1097/IAE.0b013e31827b6324

F. Ziemssen, N. Eter, S. Fauser, S. Bopp, M. Radermacher et al., Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany], Ophthalmol Z Dtsch Ophthalmol Ges, vol.112, issue.3, pp.246-54, 2015.

K. Schweitzer, A. Eneh, and J. Gale, Practice patterns of Canadian vitreoretinal specialists in diabetic macular edema treatment, Canadian Journal of Ophthalmology / Journal Canadien d'Ophtalmologie, vol.46, issue.3, pp.227-258, 2011.
DOI : 10.1016/j.jcjo.2011.05.013

J. Campbell, A. Cole, A. Almony, H. Ingraham, J. Kowalski et al., Real World Vision Ourcomes in DME Treated with Anti-VEGF Injections-An analysis of EMR Data From a Large Health System-Paper session-ARVO 2014, ARVO Annual meeting Abstrats, 2014.

V. P. Namritha, A. Sheelah, S. Dawn, S. Sobha, T. Adnan et al., Real-world ourcomes of ranibizumab treatment for diabetic macular edema-Paper session-ARVO 2015, ARVO 2015 Annual Meeting Abstracts, 2015.

M. Addou-regnard, A. Couturier, R. Hage, R. Tadayoni, and P. Massin, Résultats au long cours du traitement de l'oedème maculaire diabétique par Ranibizumab en pratique clinique-Communication Orale, pdf 152. ONDPS, Observatoire National de la Démographie des Professions de Santé

P. Massin, S. Baillif, C. Creuzot-garcher, F. Fajnkuchen, and L. Kodjikian, Recommandations FFM-Oedème maculaire diabétique: diagnostic et bilan préthérapeutique [Internet]. Fédérarion France Macula Available from

R. Klein, B. Klein, S. Moss, M. Davis, and D. Demets, The Wisconsin Epidemiologic Study of Diabetic Retinopathy, Archives of Ophthalmology, vol.102, issue.4, pp.520-526, 1960.
DOI : 10.1001/archopht.1984.01040030398010

P. Brito, V. Rosas, L. Coentrão, Â. Carneiro, A. Rocha-sousa et al., EVALUATION OF VISUAL ACUITY, MACULAR STATUS, AND SUBFOVEAL CHOROIDAL THICKNESS CHANGES AFTER CATARACT SURGERY IN EYES WITH DIABETIC RETINOPATHY, Retina, vol.35, issue.2, 2015.
DOI : 10.1097/IAE.0000000000000298

S. Kim, R. Equi, and N. Bressler, Analysis of Macular Edema after Cataract Surgery in Patients with Diabetes Using Optical Coherence Tomography, Ophthalmology, vol.114, issue.5, 2007.
DOI : 10.1016/j.ophtha.2006.08.053

T. Hong, P. Mitchell, T. De-loryn, E. Rochtchina, S. Cugati et al., Development and Progression of Diabetic Retinopathy 12 Months after Phacoemulsification Cataract Surgery, Ophthalmology, vol.116, issue.8, pp.1510-1514, 2009.
DOI : 10.1016/j.ophtha.2009.03.003

A. Das, P. Mcguire, and S. Rangasamy, Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets, Ophthalmology, vol.122, issue.7, p.2015
DOI : 10.1016/j.ophtha.2015.03.024

S. Rangasamy, P. Mcguire, and A. Das, Diabetic retinopathy and inflammation: novel therapeutic targets, Middle East Afr J Ophthalmol. 2012, vol.19, issue.1, pp.52-61

. Afssaps, Bonnes pratiques d'injection intra-vitréenne (IVT) [Internet], 2011.

C. Creuzot-garcher, A. Bron, I. Cochereau, M. Labetoulle, and B. Bodaghi, Indication de l'antibioprophylaxie lors des injections intravitréennes-SFO [Internet] Available from, 2015.

A. Bron, P. Koehrer, L. Aho-glélé, C. Creuzot-garcher, and . Frcr, FRenCh Retina specialists net) Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome, MEDECIN Am J Ophthalmol. 2015, vol.160, issue.1, pp.17-25

. Après-combien-d, IVT d'anti-VEGF considérez-vous qu'un patient est résistant (et donc non répondeur) à la molédule? 26, Quels critères peuvent vous conduire à arrêter les IVT ou à changer de molécule